ClinicalTrials.gg
RecruitingNCT06296979Updated Apr 2, 2025

Effectiveness of Noninvasive Phrenic Nerve Neuromodulation in Shoulder Pain and Hepatobiliary Visceral Comorbidity.

An interventional study of Phrenic nerve neuromodulation and common Physical therapy in Shoulder Pain, sponsored by University of Seville. Recruiting at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by University of Seville · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Shoulder Pain with a site in Spain — 10 open to participants now, 10 under way, none of them phase 3. Shoulder Pain · Spain.

Planned enrollment
40th of 49
34 · median 50
Started
2024
with 7 others
No phase
47 of 52
10 open now
Registered
34th of 52
by date
Lead sponsor
2 of 52
University of Seville

Among the 52 studies in Shoulder Pain with a site in Spain, this one is the 40th largest by planned enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2024, is one of 47 with no phase, and was the 34th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

10 of the 52 studies in Shoulder Pain with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Shoulder Pain with a site in Spain, or all of them as a file.
02

Study summary

Pain, particularly shoulder pain, is a social and economic problem worldwide. Although visceral pathology is not yet taken into account in the diagnosis of these pains, it is likely that on numerous occasions the hepatobiliary visceral condition causes referred pain in the metameric area belonging to the shoulder due to the involvement of the phrenic nerve. Therefore, the aim of this project is to study the response of treatment by neuromodulation of the phrenic nerve for shoulder pain in patients with associated hepatobiliary pathologies, assessing the possible visceral involvement in the symptomatology.

Read the detailed description

Approximately 80% of patients with liver disease suffer chronic pain and fatigue, which can lead to sensitization of the central and peripheral nervous system. Central sensitization is an increase in the responsiveness of neurons within the central nervous system, which can lead to generalized pain hypersensitivity. It has been shown that some lesions or inflammatory processes can trigger changes in the nervous system, generating persistent pain.

According to the theory of visceral referred pain, there are visceral and musculoskeletal stimuli that converge in higher centers capable of producing referred pain in regions where metameric innervation is shared. This raises the possibility that altered visceral mechanisms may provoke and chronify musculoskeletal pain.

According to this theory, people with structural or functional hepatobiliary pathologies may have referred pain in the right metameric territory of C2-C3-C4-C5, which may generate pain in the shoulder on the same side. This is due to the fact that the phrenic nerve sensitively innervates Glisson's capsule, so any affectation of this structure can generate afferent stimuli to the previously mentioned metameric levels.

The phrenic hypothesis plays a very important role today, having as its main "endorsement" the analgesic techniques of phrenic blockade used for shoulder pain after hepatectomy. In order to eliminate this post-operative shoulder pain, electrical or medical nerve blocks are used.

03

Conditions studied

  • Shoulder Pain

Browse trials for

Keywords

  • phrenic nerve
  • Shoulder Pain
  • Nuromodulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years of age.
  • Subjects presenting right shoulder pain at the time of enrollment in the study.
  • Presentation of a hepatobiliary visceral disorder that may justify the visceral etiology of the pain.
  • That they agree to participate in the project by signing the form.

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic pain due to other diseases such as malignant disease.
  • Patients with rheumatic diseases.
  • Cutaneous infection in the area of pain.
  • Disease of neurological, traumatic, oncologic, or infectious origin that rules out the visceral origin of the pain.
  • Uncooperative subject.
  • Severe psychiatric disease.
  • Loss of cognitive capacity.
  • to electrotherapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (estimated)

Study arms

  • Active comparator
    USUAL PHYSIOTHERAPY

    the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.

    Procedure: common Physical therapy

  • Experimental
    Transcutaneous electrical nerve stimulation

    The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.

    Device: Phrenic nerve neuromodulation · Procedure: common Physical therapy

Interventions

  • DevicePhrenic nerve neuromodulation

    The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.

  • Procedurecommon Physical therapy

    the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.

06

What researchers measure

Primary outcomes

  1. Numeric Pain Rating Scale

    Perceived pain. Self-perceived pain intensity will be evaluated by a 0 to 10 Numeric Pain Rating Scale (NPRS), where 0 denotes no pain and 10 denotes the maximum possible pain.

    Time frame: pre-treatment, 1 week, 4 week, 12 week.

Secondary outcomes

  1. Algometry

    Pain threshold to pressure at specific tender points of the shoulder: infraspinatus, deltoid and trapezius. PPT levels defined as the minimum pressure required to evoke pain will be assessed using a portable electronic pressure algometer. Change from baseline on algometry. The units of measurement of pressure pain will be Kg/cm2.

    Time frame: pre-treatment, 1 week, 4 week, 12 week.

  2. Goniometry passive

    measurement of passive pain-free ranges of motion of flexion, internal rotation, external rotation and abduction of the right shoulder with a portable goniometer. the unit of measurement shall be the degree of movement.

    Time frame: pre-treatment, 1 week, 4 week, 12 week.

  3. Quick Dash questionnaire

    Questionnaire that measures the function of the upper limb. It is composed of 11 items that are rated from 1 to 5, from least to most difficult to perform certain movements.

    Time frame: pre-treatment, 1 week, 4 week, 12 week.

  4. Goniometriy active

    measurement of active pain-free ranges of motion of flexion, internal rotation, external rotation and abduction of the right shoulder with a portable goniometer. the unit of measurement shall be the degree of movement.

    Time frame: pre-treatment, 1 week, 4 week, 12 week.

07

Study locations

4 of 4 sites recruiting
  • Centro de especialidades Morón de la Frontera
    Morón de la Frontera, Seville 41530, Spain
    Recruiting
  • Centro de Salud Ronda Histórica
    Sevilla, 41008, Spain
    Recruiting
  • Centro de Salud las Letanías
    Sevilla, 41013, Spain
    Recruiting
  • Centro de Salud Bellavista
    Sevilla, 41014, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 32 months is above that.

Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 6, 2024
StartActual
Mar 20, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06296979
Responsible party
Angel Oliva Pascual-Vaca (Doctor, University of Seville) — Principal investigator
First posted
Mar 6, 2024
Start date
Mar 20, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 2, 2025

Study contacts

Adolfo Rosado Portillo
Contact
adolforosadoportillo@gmail.com
605663879
Ángel Oliva Pascual-Vaca, Dr
principal investigator · University of Seville

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion